Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shom Goel

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Journal of the National Cancer Institute|February 25, 2015
Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapyEleanor I Ager, Sergey V Kozin, Nathaniel D Kirkpatrick, et al.
Cancer Discovery|December 4, 2023
INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid TumorsCatherine Dietrich, Alec Trub, Antonio Ahn, et al.
Cancer Research|June 29, 2017
Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated ImmunotherapyYang Zhao, Ka Ka Ting, Jia Li, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2026
CDK4/6 Inhibition Enhances CAR-T Cell Therapy in Solid TumorsEmily J Lelliott, Jonathan Naddaf, Kun-Hui Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2024
Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable TherapiesBojana Jovanović, Sarah E Church, Kara M Gorman, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancerAna C Garrido-Castro, Noah Graham, Lestat R Ali, et al.
Cell Death and Differentiation|September 11, 2024
Intracellular zinc protects tumours from T cell-mediated cytotoxicityEmily J Lelliott, Jonathan Naddaf, Katherine Ganio, et al.
The Lancet. Oncology|May 1, 2020
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trialSara M Tolaney, Andrew M Wardley, Stefania Zambelli, et al.
Cancer Cell|March 16, 2016
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 InhibitorsShom Goel, Qi Wang, April C Watt, et al.
NPJ Breast Cancer|February 13, 2026
Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancerPaolo Tarantino, Jaeyoon Cha, Busem Binboga Kurt, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Journal of the National Cancer Institute|February 25, 2015
Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapyEleanor I Ager, Sergey V Kozin, Nathaniel D Kirkpatrick, et al.
Cancer Discovery|December 4, 2023
INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid TumorsCatherine Dietrich, Alec Trub, Antonio Ahn, et al.
Cancer Research|June 29, 2017
Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated ImmunotherapyYang Zhao, Ka Ka Ting, Jia Li, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2026
CDK4/6 Inhibition Enhances CAR-T Cell Therapy in Solid TumorsEmily J Lelliott, Jonathan Naddaf, Kun-Hui Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2024
Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable TherapiesBojana Jovanović, Sarah E Church, Kara M Gorman, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancerAna C Garrido-Castro, Noah Graham, Lestat R Ali, et al.
Cell Death and Differentiation|September 11, 2024
Intracellular zinc protects tumours from T cell-mediated cytotoxicityEmily J Lelliott, Jonathan Naddaf, Katherine Ganio, et al.
The Lancet. Oncology|May 1, 2020
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trialSara M Tolaney, Andrew M Wardley, Stefania Zambelli, et al.
Cancer Cell|March 16, 2016
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 InhibitorsShom Goel, Qi Wang, April C Watt, et al.
NPJ Breast Cancer|February 13, 2026
Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancerPaolo Tarantino, Jaeyoon Cha, Busem Binboga Kurt, et al.
Pageof 7